Whitehawk Therapeutics Inc Stock Price, News & Analysis

Whitehawk Therapeutics (NASDAQ: WHWK), a company focused on developing advanced ADC cancer treatments, announced its participation in the H.C. Wainwright virtual "HCW@Home" series. The company's President and CEO Dave Lennon, PhD, and Chief Scientific Officer David Dornan, PhD, will present on Thursday, June 26, 2025, at 10 AM ET. The presentation will be accessible via webcast on the company's website under the "Investors & News" section, with replay available for approximately 30 days after the event.

Whitehawk Therapeutics (NASDAQ: WHWK), an oncology therapeutics company focused on ADC cancer treatments, will participate in the Jefferies 2025 Global Healthcare Conference in New York City from June 3-5, 2025. CEO Dave Lennon will deliver a company overview presentation on June 4, 2025, from 2:00-2:30 PM ET. The presentation will be available via webcast on the company's IR website and accessible for replay for approximately 30 days after the event.

Whitehawk Therapeutics (NASDAQ: WHWK), an oncology therapeutics company focused on ADC cancer treatments, announced that its CEO Dave Lennon, PhD, will participate in a fireside chat at the TD Cowen 6th Annual Oncology Innovation Summit. The event is scheduled for May 28, 2025, at 2:30 PM ET. Investors can access the live webcast through Whitehawk's IR website, with the recording remaining available for approximately 30 days after the event.

[]

Whitehawk Therapeutics (NASDAQ: WHWK) reported Q1 2025 financial results and corporate updates. The company has relaunched as an ADC-focused oncology therapeutics company with three assets targeting PTK7, MUC16, and SEZ6. Key financial highlights include cash position of $231.1M as of March 31, 2025, up from $47.2M in December 2024, supported by a $100M PIPE financing and the $102.4M divestiture of Aadi Subsidiary to Kaken Pharmaceuticals. Q1 2025 saw revenue of $7.1M from FYARRO sales and net income of $73M, including an $87.4M gain from the Aadi sale. The company expects its current cash position of approximately $185M to fund operations into 2028 and remains on track to file its first IND in Q4 2025, with all three assets targeted for IND submission by mid-2026.

Whitehawk Therapeutics (Nasdaq: WHWK) has successfully completed its strategic transformation by closing the sale of its Aadi Subsidiary to Kaken Pharmaceuticals for $100 million plus customary adjustments. The transaction, initially announced in December 2024, includes the transfer of Aadi Bioscience name, trademarks, and the FYARRO® business.

The company plans to utilize proceeds from both this divestiture and a recent $100M PIPE financing to advance its antibody drug conjugates (ADCs) portfolio and for general corporate purposes. The combined funding is projected to sustain operations until 2028, supporting key clinical data readouts for three assets.

Whitehawk Therapeutics (Nasdaq: WHWK), formerly Aadi Bioscience, announced its strategic transformation into an ADC-focused oncology company. The company will begin trading under the ticker 'WHWK' on March 19, 2025.

The company's portfolio includes three assets in-licensed from WuXi Biologics, utilizing HANGZHOU DAC's advanced ADC technology platform. These assets feature a stable linker delivering a Topoisomerase I inhibitor payload, targeting lung and ovarian cancers with minimal off-target toxicity.

Following recent developments, including a $100 million PIPE financing and pending divestiture of Aadi Subsidiary to Kaken Pharmaceuticals, Whitehawk expects cash reserves of $170-180 million, funding operations into 2028. The company reported Q4 2024 revenue of $7.2 million and full-year 2024 revenue of $26.0 million from FYARRO sales, with a Q4 net loss of $18.3 million and full-year net loss of $63.7 million.